Sign in
Stories
Acadia Pharmaceuticals Appoints New Executives
Share
Acadia Realty Trust's Q4 Earnings Announ...
Amarin Q1 2024 Financial Update
Medical Companies' Financial Updates
Acadia Realty Trust Raises Capital
Acadian Timber's Resilient Performance
Reviva Pharmaceuticals to Present Therap...
Overview
API
Acadia Pharmaceuticals appoints new executive team members, Jennifer J. Rhodes as Chief Legal Officer and Kimberly J. Manhard as Global Strategic Planning and Execution, while Austin D. Kim leaves the company. The company is focused on developing treatments for various neurological conditions.
Ask a question
How does the company's focus on neurological conditions align with broader trends in the pharmaceutical industry?
How might the new appointments impact Acadia Pharmaceuticals' strategic direction and product development?
What challenges or opportunities does Acadia Pharmaceuticals face in its focus on neurological treatments?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Jan 2024
Coverage